News Sentiment

EOLS sentiment intelligence

Evolus Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 6.61 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.2% over one week, -1.8% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -4.2% Price reacting lower
Trend fit Trend active -1.8% over four weeks
Fair value -33.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 6
TradingKey 6
Market source 6
Stock Titan 4
Business Wire 4
Investing.com 3
simplywall.st 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 16
Deals and strategy 5
Analyst action 4
Guidance 3
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)

This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a "Strong Buy" consensus with a significant upside, while Penumbra (PEN) garnered a "Hold" consensus. Evolus (EOLS) also received a "Strong Buy" consensus rating

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 12:12
Source
The Globe and Mail
Yahoo! Finance Canada Direct company coverage

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. announced the grant of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees between April and July 2026. These inducement awards were approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, as material inducemen

Tone
Positive 61/100
Event
Market update
Published
10 Jul 2026 16:05
Source
Yahoo! Finance Canada
TMX Newsfile Direct company coverage

Evolus Class Action Reminder

Faruqi & Faruqi, LLP is reminding investors who suffered losses exceeding $100,000 in Evolus (NASDAQ: EOLS) stock or options between February 1, 2019, and July 6, 2020, to contact them. The firm is investigating potential claims that Evolus made misleading statements regarding it

Tone
Negative 29/100
Event
Market update
Published
10 Jul 2026 08:39
Source
TMX Newsfile
TradingView Direct company coverage

ETFs Investing in Evolus, Inc. Stocks

This article lists various ETFs that invest in Evolus, Inc. (EVL) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM. The funds primarily focus on small-cap, total market, micro-cap, and healthcare sectors, offering investors

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 08:40
Source
TradingView
Moomoo Direct company coverage

Evolus Partners With IBSA to Develop, Commercialize Profhilo in US

Evolus has partnered with IBSA to develop and commercialize Profhilo, an injectable aesthetic treatment, in the United States. This collaboration aims to bring a new bio-remodeling product to the US market, expanding Evolus's portfolio beyond neuromodulators and adding an immedia

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 03:39
Source
Moomoo
The Dermatology Digest Direct company coverage

Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US

Evolus has entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, a hyaluronic acid-based injectable for skin quality improvement, in the United States. This partnership expands Evolus's presence in the aesthetic market, ta

Tone
Positive 72/100
Event
Deals and strategy
Published
08 Jul 2026 15:39
Source
The Dermatology Digest
Investing.com Direct company coverage

Evolus signs licensing deal for Profhilo skin injectable in US

Evolus Inc. has signed an exclusive licensing and distribution agreement with IBSA to commercialize Profhilo, a hyaluronic acid skin injectable, in the United States. This agreement allows Evolus to expand its aesthetic product portfolio, complementing its existing neurotoxin and

Tone
Positive 67/100
Event
Deals and strategy
Published
08 Jul 2026 13:39
Source
Investing.com
Investing.com Canada Direct company coverage

Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com

Evolus Inc. has signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo, a hyaluronic acid skin injectable, to the United States. This strategic move expands Evolus's aesthetic product portfolio, which already includes Jeu

Tone
Positive 74/100
Event
Deals and strategy
Published
08 Jul 2026 13:18
Source
Investing.com Canada
TradingView Direct company coverage

Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term

Evolus has secured an exclusive 15-year U.S. license, supply, and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin quality. Evolus will manage the U.S. development, clinical work, and regulatory approval, with no upfront or milestone p

Tone
Positive 71/100
Event
Regulatory and legal
Published
08 Jul 2026 13:13
Source
TradingView
Stock Titan Direct company coverage

Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries

Evolus, Inc. announced an exclusive licensing and distribution agreement with IBSA to bring Profhilo®, a leading skin-quality injectable, to the United States. This partnership expands Evolus's injectable portfolio into the rapidly growing skin quality segment, complementing its

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 13:12
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Evolus, Inc. has partnered with IBSA to exclusively license and commercialize Profhilo® in the United States, expanding Evolus's injectable portfolio into the skin quality segment. Profhilo® is a market-leading injectable in Europe designed to improve skin quality, hydration, ela

Tone
Positive 72/100
Event
Deals and strategy
Published
08 Jul 2026 09:00
Source
Yahoo! Finance Canada
Stock Traders Daily Direct company coverage

(EOLS) and the Role of Price-Sensitive Allocations

This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated signals for July 7, 2026. It highlights a near-term weak sentiment but mid-term strength within a broader long-term weak bias, noting compelling upside potential due to the absence of resistance

Tone
Negative 36/100
Event
Market update
Published
07 Jul 2026 03:16
Source
Stock Traders Daily
Finviz Direct company coverage

EOLS - Evolus Inc Options

This page provides a detailed financial overview of Evolus Inc (EOLS) options, including its latest stock price, financial metrics, and performance indicators. It covers market capitalization, income, sales, various ratios, insider ownership, institutional ownership, profitabilit

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:11
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS

This page from TradingView provides financial information for Evolus, Inc. Common Stock (NASDAQ: EOLS), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's financial overview within the health technology and pharmaceutical sectors.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 13:09
Source
TradingView
MSN Direct company coverage

Evolus (EOLS) price target decreased by 11.11% to 14.96

The price target for Evolus (EOLS) has been decreased by 11.11%, bringing it down to $14.96. Further details are not available in the provided content.

Tone
Negative 30/100
Event
Analyst action
Published
28 Jun 2026 11:09
Source
MSN
TradingView Direct company coverage

Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS)

This article provides actuals and estimates for Evolus, Inc. (NASDAQ:EOLS), including financial data, analyst forecasts, and various stock performance metrics. It covers the company's current stock price, historical highs and lows, volatility, market capitalization, and earnings

Tone
Positive 61/100
Event
Earnings
Published
26 Jun 2026 09:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS

This article provides access to the "Price to sales forward" financial metric for Evolus, Inc. Common Stock (NASDAQ: EOLS) on the TradingView platform. It highlights that this data is part of the financials section for EOLS, indicating its availability for users analyzing the com

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:09
Source
TradingView
TradingView Direct company coverage

EOLS Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Evolus, Inc. (EOLS) stock for 2027, based on analyst ratings and the company's financial performance. It includes current stock price information, historical highs and lows, market capitalization, volatility, and details on ear

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 16:09
Source
TradingView
TradingKey Direct company coverage

Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evolus Inc (EOLS), detailing its price momentum score of 9.32 within the Pharmaceuticals industry. It identifies current support at $6.35 and resistance at $7.55, suggesting suitability for range-bound swing trading. The analysis incl

Tone
Positive 76/100
Event
Market update
Published
24 Jun 2026 09:09
Source
TradingKey
Kavout Direct company coverage

Is Evolus (EOLS) Finally Turning the Corner on Profitability

Evolus (EOLS) reported strong Q1 2026 results, beating revenue expectations with $73.1 million, driven by demand for Jeuveau and growth in Evolisse. The company achieved its second consecutive quarter of positive Adjusted EBITDA, signaling progress toward full-year profitability

Tone
Positive 64/100
Event
Earnings
Published
21 Jun 2026 00:40
Source
Kavout
TradingKey Direct company coverage

Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis

Evolus Inc (EOLS) has a financial score of 8.00, placing it 84th out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $73.14M, marking a 6.74% year-over-year increase, and net pro

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 19:09
Source
TradingKey
TradingKey Direct company coverage

Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Evolus Inc (EOLS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays current stock information for EOLS, including

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 11:40
Source
TradingKey
TradingKey Direct company coverage

Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evolus Inc (EOLS), identifying major shareholders by proportion and type, as well as institutional holdings over various quarters. It highlights key individual and institutional investors and their recent activities, alongside rel

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:40
Source
TradingKey
TradingKey Direct company coverage

Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evolus Inc (EOLS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus "Buy" rating for EOLS, with an average price target of $19.50, suggesting a significant upside of over 121% from its current price of $6.63. The expec

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:40
Source
TradingKey
GuruFocus Direct company coverage

EOLS Reiterated by BTIG -- Price Target Maintained at $13.00

BTIG has reiterated a Buy rating for Evolus (EOLS), maintaining a price target of $13.00. Despite strong growth potential (GF Score Growth 10/10), the company faces challenges in Financial Strength and Profitability (both 3/10). The stock is considered 51.0% undervalued by GuruFo

Tone
Positive 67/100
Event
Analyst action
Published
17 Jun 2026 11:10
Source
GuruFocus
TradingKey Direct company coverage

Evolus Inc (EOLS) Institutional Confidence

Evolus Inc (EOLS) has an institutional shareholding score of 7.00, ranking 51st in the Pharmaceuticals industry. The institutional shareholding proportion is 75.98%, a decrease of 14.84% quarter-over-quarter. James Simons is the largest institutional shareholder, with other signi

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 05:40
Source
TradingKey
Stock Titan Direct company coverage

[EFFECT] Evolus, Inc. SEC Filing

This article provides details on an SEC filing (Form EFFECT) by Evolus, Inc. The filing indicates an effectiveness date of June 12, 2026, for Form S-3. It also includes company information, recent news, and other SEC filings for Evolus.

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 10:39
Source
Stock Titan
Stock Traders Daily Direct company coverage

Understanding the Setup: (EOLS) and Scalable Risk

This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) using AI models to suggest trading strategies. It highlights mixed sentiment, potential upside due to lack of resistance, and offers specific position trading, momentum breakout, and risk hedging strategies. The anal

Tone
Positive 64/100
Event
Market update
Published
15 Jun 2026 00:56
Source
Stock Traders Daily